We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BODITECH

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. Its products include automatic ... read more Featured Products: More products

Download Mobile App





Boditech Presents Latest IVD Solutions at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022

Boditech Med (Gang-won-do, Korea) presented its latest IVD solutions, including RDTs, fluorescence immunoassay tests, and PCR tests, at ECCMID 2022. More...

Boditech demonstrated its AFIAS-10 automated immunoassay analyzer with blood collection tube, including an all-in-one cartridge system. The CE Marked AFIAS-10 is a unique integrated sample-to-answer system that can execute 10 parallel tests for each different parameter. It provides a quick and simplified operation and reliable test results with automatically collection of sample from a blood tube. Also on display was Boditech’s ichroma II, a compact and easy-to-use, fluorescence based POCT immunoassay analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases. Alongside this, Boditech presented ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters. ichroma III accepts cartridges for various biomarkers in random sequence and processes them in a preset temperature, even combines test parameters with differing incubation period.

At this year’s ECCMID, Boditech showcased its NuActor bench-top & automated nucleic acid (RNA/DNA) extraction system used with a ready-to-use cartridge that can be stored at room temperature as a table-top extractor. It can extract concentrated high-purity nucleic acids from a small volume of samples such as blood, cultured cells, and animal tissues quickly and easily. Visitors to Boditech’s ECCMID booth also experienced ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges. ExAmplar employs relatively fast thermal cycles (~40 sec) and can deliver the DNA and RNA test results in 30 and 45~55 minutes, respectively. The system runs with dedicated 8-well plates. The reagents for the test come in a dry format, which can be stored at room temperature.

Related Links:
Boditech Med 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
All-in-One Molecular System
AIO M160
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.